Previous symbols: DHTR, SBMA. Aliases: AIS, NR3C4, SMAX1, HUMARA.
The androgen receptor (AR; NR3C4) is an intracellular steroid receptor with an N-terminal transcriptional activation domain containing a polymorphic polyglutamine tract, a zinc-finger DNA-binding domain and a C-terminal ligand-binding domain. Full-length AR recognizes androgens, moves between cytosolic and nuclear pools, binds regulatory DNA and recruits context-dependent coactivators or corepressors to control transcription. It supports male sexual differentiation, reproductive function and tissue-specific androgen responses. Alternative products, including AR-V7, can alter ligand dependence and transcriptional behavior. The disordered activation domain supports molecular condensation as one mode of receptor assembly. Loss-of-function variants cause androgen insensitivity, whereas expansion of the CAG-encoded polyglutamine tract causes spinal and bulbar muscular atrophy. Dysregulated AR signaling, including altered abundance, ligand responses and splice products, contributes to prostate cancer progression.
Relationship is the entry's genetic[].relationship_type. untyped means the entry has a genetic record for the gene but does not type it; its free-text association is shown instead.
| Disorder | Relationship | Where the gene appears |
|---|---|---|
| Androgen Insensitivity Syndrome | causative |
mechanism: Pathogenic AR Variation
subtype: CAIS; MAIS; PAIS
animal model: Sertoli-cell androgen receptor knockout mouse; Ubiquitous androgen receptor knockout mouse
|
| Androgenetic Alopecia | susceptibility germline |
mechanism: Dihydrotestosterone-Androgen Receptor Signaling; Polygenic Susceptibility; Regional Androgen Receptor Abundance
|
| Vulvodynia | susceptibility |
mechanism: Androgen Receptor Signalling Insufficiency
|
| Benign Prostatic Hyperplasia |
untyped
Risk Factor
|
|
| Kennedy Disease |
untyped
Causative
|
treatment: Antisense oligonucleotide AR-lowering therapy (experimental)
diagnosis: Molecular genetic testing
|
| Klinefelter Syndrome |
untyped
Androgen signaling pathway
|
|
| Polycystic Ovary Syndrome |
untyped
Risk Factor
|
|
| Prostate Adenocarcinoma |
untyped
Amplification, activating mutation, or splice variant expression during progression
|
|
| BRCA-Mutant Prostate Cancer | no genetic record |
mechanism: PARP-Androgen Receptor Co-Dependency
|
An entry matches when ClinGen's MONDO disease is the entry's own disease term, a subtype term, or an exact-match mapping. An amber status marks an entry ClinGen supports the gene for (Definitive, Strong or Moderate) whose own record does not type it. A Limited, Disputed or Refuted tier on such an entry is not a gap.
| ClinGen disease | MOI | Classification | dismech entry |
|---|---|---|---|
| Kennedy disease MONDO:0010735 | XL | Definitive 2023-08-08 |
Kennedy Disease
untyped
|
Identity from HGNC (snapshot 2026-10-01). Page layers are described in the gene pages documentation.